Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation
May 1, 2014, 00:00
10.1016/j.jval.2014.03.441
https://www.valueinhealthjournal.com/article/S1098-3015(14)00492-6/fulltext
Title :
Budget Impact Analysis of Bevacizumab Plus Chemotherapy Versus Bevacizumab and Anti-Egfr With Chemotherapy for First and Second Line Treatment of Metastatic Colorectal Cancer in Russian Federation
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)00492-6&doi=10.1016/j.jval.2014.03.441
First page :
A75
Section Title :
Cancer
Open access? :
No
Section Order :
1487